Preclinical development of metalloproteasis inhibitors in cancer therapy

Critical Reviews in Oncology/Hematology

Volumn 37, Issue 1, 2001, Pages 53-60

  Giavazzi, Raffaella ^a   Taraboletti, Giulia ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Angiogenesis; Matrix metalloproteasis inhibitors; Metastasis; Preclinical models; Proteasis

Indexed keywords

BATIMASTAT; CGS 27023A; MARIMASTAT; MATRIX METALLOPROTEINASE; METALLOPROTEINASE; PRINOMASTAT; REBIMASTAT; TANOMASTAT; TETRACYCLINE DERIVATIVE; TISSUE INHIBITOR OF METALLOPROTEINASE;

ANGIOGENESIS; BEAR; CANCER; CANCER GROWTH; CANCER THERAPY; DRUG DEVELOPMENT; DRUG EFFECT; EXTRACELLULAR MATRIX; METASTASIS; REVIEW; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HUMANS; METALLOENDOPEPTIDASES; NEOPLASM INVASIVENESS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0035152482     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(00)00096-2     Document Type: Review

References (69)

1. ECM and cell surface proteolysis: regulating cellular ecology
2. The role of proteolytic enzymes in cancer invasion and metastasis
3. Biology and biochemistry of proteinases in tumor invasion
4. Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis
5. Changing views of the role of matrix metalloproteinases in metastasis
6. Regulation of matrix metalloproteinase expression in tumor invasion
7. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response
8. Matrix metalloproteinase inhibitors
9. Reduced angiogenesis and tumor progression in gelatinase - a deficient mice
10. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention
11. Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance
12. Macrophage-derived metalloelastase is responsible for the generation of angiiostatin in Lewis lung carcinoma
13. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/Type IV collagenase (MMP-9)
14. Matrix metalloproteinases
15. Structural biochemistry and activation of matrix metalloproteases
16. A metalloproteinase disintegrin that releases tumour necrosis factor-alpha from cells
17. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha
18. Processing of tumour necrosis factor-α precursor by metalloproteinases
19. Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor
20. Partial purification and characterization of a neutral protease which cleaves type IV collagen
21. Metalloproteinases in tumor progression: the contribution of MMP-9
22. Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma
23. Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer
24. Association of MMP-2 activation potential with metastatic progression in human breast cancer cell lines independent of MMP-2 production
25. Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer
26. Production of extracellular matrix-degrading proteinases by primary cultures of human epithelial ovarian carcinoma
27. Growth factor-regulated proteases and extracellular matrix remodeling during mammalian development
28. Cytokine regulation of metalloproteinase gene expression
29. A matrix metalloproteinase expressed on the surface of invasive tumour cells
30. Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation
31. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity
32. Matrix metalloproteinase inhibitors
33. Matrix metalloproteinase inhibitors and cancer
34. X-ray structures of human neutrophil collagenase complexed with peptide hydroxamate and peptide thiol inhibitors. Implications for substrate binding and rational drug design
35. Structure of the catalytic domain of fibroblast collagenase complexed with an inhibitor
36. Matrix metalloproteinase inhibition: a review of anti-tumor activity
37. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation
38. Combined analysis of studies of the effects of the matrix metalloprotease inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for long-term studies
39. Inhibition of the metastatic spread and growth of B16-Bl6 murine melanoma by a synthetic matrix metalloproteinase inhibitor
40. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94)
41. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumour growth and spread in a patient-like orthotopic model in nude mice
42. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models
43. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice
44. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts
45. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts
46. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases
47. Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites
48. Phase I trial of marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer
49. Results of a single and repeated dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers
50. Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases
51. AG3340, a novel MMP inhibitor, has a superior therapeutic index to carboplatin in mice bearing chemoresistant human MV522 lung cancer tumors
52. A phase I study of AG3340, a matrix metalloprotease (MMP) inhibitor, in patients having advanced cancer
53. CGS 27023A, a potent and orally active matrix metalloprotease inhibitor with antitumor activity
54. A phase one pharmacokinetic study of CGS27023A, a matrix metalloproteinase inhibitor
55. Activities of a synthetic matrix metalloproteinase inhibitor (MMPI), BMS-275291, in models of angiogenesis and tumor metastasis
56. BAY 12-9566, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity
57. Anti-metastatic activity of BAY 12-9566 in human colon carcinoma HCT116 orthotopic model
58. Activity of the biphenyl matrix metalloproteinase inhibitor BAY 12-9566 in murine in vivo models
59. Clinical pharmacology of the metalloproteinase (MMP) and angiogenesis inhibitor Bay 12-9566 in cancer patients
60. Neovastat: an inhibitor of angiogenesis with anticancer activity
61. Angiogenesis inhibition by minocycline
62. Toxicity of COL-3 to rats and monkeys
63. Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma
64. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases
65. AG3340, a selective MMP inhibitor, has broad antiangiogenic activity across oncology and ophtalmology models in vivo
66. Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension
67. M(r) 92 000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer
68. Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients
69. Increased incidence of matrix metalloproteinases in urine of cancer patients